Kiniksa Pharmaceuticals (KNSA) Revenue & Revenue Breakdown
Kiniksa Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$270.26M
Latest Revenue (Q)
$112.21M
Main Segment (Y)
Product
Kiniksa Pharmaceuticals Revenue by Period
Kiniksa Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $270.26M | 22.74% |
| 2022-12-31 | $220.18M | 471.24% |
| 2021-12-31 | $38.54M | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | - |
Kiniksa Pharmaceuticals generated $270.26M in revenue during NA 2023, up 22.74% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Kiniksa Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | $112.21M | 3.30% |
| 2024-06-30 | $108.63M | 36.03% |
| 2024-03-31 | $79.86M | -4.24% |
| 2023-12-31 | $83.39M | 24.38% |
| 2023-09-30 | $67.05M | -6.19% |
| 2023-06-30 | $71.47M | 47.84% |
| 2023-03-31 | $48.34M | -21.88% |
| 2022-12-31 | $61.88M | -37.58% |
| 2022-09-30 | $99.14M | 267.55% |
| 2022-06-30 | $26.97M | -16.21% |
| 2022-03-31 | $32.19M | 71.72% |
| 2021-12-31 | $18.75M | 54.98% |
| 2021-09-30 | $12.10M | 57.00% |
| 2021-06-30 | $7.70M | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | - |
Kiniksa Pharmaceuticals generated $112.21M in revenue during Q3 2024, up 3.30% compared to the previous quarter, and up 157.00% compared to the same period a year ago.
Kiniksa Pharmaceuticals Revenue Breakdown
Kiniksa Pharmaceuticals Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 |
|---|---|---|
| Product | $233.18M | $122.52M |
| Collaboration | $37.08M | $97.66M |
Latest
Kiniksa Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (86.28%), and Collaboration (13.72%).
Quarterly Revenue by Product
| Product/Service | Sep 24 | Jun 24 | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 |
|---|---|---|---|---|---|---|---|---|---|
| Collaboration | $6.21M | $5.24M | $14.42M | $16.98M | $5.69M | $21.95M | - | - | - |
| Product | $112.21M | $103.39M | $136.02M | $54.49M | $42.66M | $39.94M | $33.42M | $26.97M | $22.19M |
Latest
Kiniksa Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Product (94.76%), and Collaboration (5.24%).
Kiniksa Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| KNSA | Kiniksa Pharmaceuticals | $270.26M | $112.21M |
| CHRS | Coherus BioSciences | $257.24M | $70.77M |
| ACLX | Arcellx | $110.32M | $26.03M |
| SPRO | Spero Therapeutics | $96.73M | $13.47M |
| BOLT | Bolt Biotherapeutics | $7.88M | $1.14M |
| KRON | Kronos Bio | $6.29M | $2.37M |
| LYRA | Lyra Therapeutics | $1.56M | $195.00K |
| PHAT | Phathom Pharmaceuticals | $682.00K | $16.35M |
| CGEM | Cullinan Oncology | - | - |
| GPCR | Structure Therapeutics | - | - |
| NUVL | Nuvalent | - | - |
| COGT | Cogent Biosciences | - | - |
| GOSS | Gossamer Bio | - | $9.48M |
| DAWN | Day One Biopharmaceuticals | - | $20.07M |
| REPL | Replimune Group | - | - |
| KURA | Kura Oncology | - | - |
| VTYX | Ventyx Biosciences | - | - |
| LRMR | Larimar Therapeutics | - | - |
| NVCT | Nuvectis Pharma | - | - |